HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays

Table 4 Specificity, sensitivity, positive and negative predictive values and the area under the receiver operating characteristic curve of each antibody according to the final human epidermalgrowth factor receptor 2 status

		HercepTest (95%CI)	4B5 (95%CI)	SP3 (95%CI)
TMA	Sensitivity	42.9 (21.7-64.0)	57.1 (35.9-78.3)	66.7 (46.5-86.8)
	Specificity	99.4 (98.3-100.0)	100.0	93.1 (89.4-96.9)
	PPV	90.0 (71.4-100.0)	100.0	53.8 (34.7-73.0)
	NPV	93.6 (90.1-97.1)	95.1 (92.0-98.2)	95.9 (92.9-98.9)
	AUC	0.71 (0.60-0.782)	0.79 (0.68-0.89)	0.80 (0.69-0.90)
Whole-tissue sections	Sensitivity	47.6 (26.2-68.9)	95.2 (86.1-100.0)	90.5 (77.9-100.0)
	Specificity	99.4 (98.3-100.0)	87.0 (82.0-91.9)	81.2 (75.5-87.0)
	PPV	90.9 (73.9-100.0)	46.5 (31.6-61.4)	36.5 (23.4-49.6)
	NPV	94.1 (90.7-97.5)	99.3 (98.1-100.0)	98.6 (96.7-100.0)
	AUC	0.73 (0.63-0.84)	0.91 (0.86-0.96)	0.86 (0.78-0.93)

PPV: Positive predictive value; NPV: Negative predictive value; AUC: Area under the receiver operating characteristic curve; TMA: Tissue microarray.